• Exchange: Toronto
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Spectral Diagnostics Inc

+ Add to Watchlist


0.3200 CAD 0.00000.00%

As of 15:59:20 ET on 10/21/2014.

Snapshot for Spectral Diagnostics Inc (SDI)

Open: 0.3300 Day's Range: 0.3150 - 0.3300 Volume: 55,681
Previous Close: 0.3200 52wk Range: 0.2200 - 0.7700 1-Yr Rtn: -39.62%

Stock Chart for SDI

No chart data available.
  • SDI:CN 0.3200
  • 1D
  • 1M
  • 1Y
Interactive SDI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SDI

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPTSX -
Earnings Per Share (CAD) (ttm) -0.0900
Est. EPS (CAD) (12/2014) -0.0400
Est. PEG Ratio -
Market Cap (M CAD) 57.44
Shares Outstanding (M) 179.51
30 Day Average Volume 72,685
Price/Book (mrq) 131.5843
Price/Sale (ttm) 14.2304
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/13/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SDI

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for SDI

Spectral Diagnostics is inPhase III, seeking FDA approval for its theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay, Spectral's EUPHRATES trial is a theranostics trial in the area of sepsis.

Paul M WalkerPresident/CEOAnthony BusinskasExec VP/CFO/Secy
Debra FosterVP:Clinical Development
More Company Profile & Key Executives for SDI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil